| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Ciro Menale | Q42787732 |
| P2093 | author name string | Anna Villa | |
| Cristina Sobacchi | |||
| P2860 | cites work | Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations | Q24310432 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| Central control of fever and female body temperature by RANKL/RANK | Q24321735 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer | Q24605866 | ||
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate | Q24658507 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Bone Marrow T Cells and the Integrated Functions of Recirculating and Tissue-Resident Memory T Cells | Q26766714 | ||
| An overview of the intrathymic intricacies of T cell development | Q26862512 | ||
| Thymic epithelial cell development and differentiation: cellular and molecular regulation | Q27004003 | ||
| Antigen recognition by autoreactive CD4⁺ thymocytes drives homeostasis of the thymic medulla | Q27324446 | ||
| Identification of novel thymic epithelial cell subsets whose differentiation is regulated by RANKL and Traf6 | Q27331912 | ||
| RANKL/RANK: from bone loss to the prevention of breast cancer | Q28075004 | ||
| The thymus and rheumatology: should we care? | Q28080019 | ||
| Matrix-embedded cells control osteoclast formation | Q28247746 | ||
| Evidence for osteocyte regulation of bone homeostasis through RANKL expression | Q28247757 | ||
| Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab | Q28265584 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Dependence of self-tolerance on TRAF6-directed development of thymic stroma | Q28590193 | ||
| Normal thymic architecture and negative selection are associated with Aire expression, the gene defective in the autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) | Q28590962 | ||
| IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells | Q28591227 | ||
| Expression of relB is required for the development of thymic medulla and dendritic cells | Q28594949 | ||
| Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis | Q28943317 | ||
| The pathogenesis of rheumatoid arthritis | Q29614957 | ||
| Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance | Q33569842 | ||
| Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis. | Q33592037 | ||
| Thymic homing of activated CD4+ T cells induces degeneration of the thymic epithelium through excessive RANK signaling | Q33729251 | ||
| Administration of RANKL boosts thymic regeneration upon bone marrow transplantation | Q33748998 | ||
| Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction | Q33886695 | ||
| Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family | Q34317095 | ||
| Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond | Q34366449 | ||
| Limitation of immune tolerance-inducing thymic epithelial cell development by Spi-B-mediated negative feedback regulation | Q34533105 | ||
| Thymopoiesis in Pre- and Post-Hematopoietic Stem Cell Transplantation | Q58758833 | ||
| Coupling of bone resorption and formation by RANKL reverse signalling | Q59051790 | ||
| RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation | Q59806646 | ||
| Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy | Q60489259 | ||
| Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss | Q61135621 | ||
| Autoantigen-Specific Interactions with CD4+ Thymocytes Control Mature Medullary Thymic Epithelial Cell Cellularity | Q63190413 | ||
| Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone. | Q64900637 | ||
| Enhanced secretion of IFN-gamma by activated Th1 cells occurs via reverse signaling through TNF-related activation-induced cytokine | Q73311846 | ||
| Immune system and bone metabolism: Does thymectomy influence postmenopausal bone loss in humans? | Q83322481 | ||
| Effects of RANKL on the thymic medulla | Q84449609 | ||
| Denosumab for post-transplantation hypercalcemia in osteopetrosis | Q85323651 | ||
| Rheumatoid arthritis | Q87726283 | ||
| Invariant NKT Cells and Control of the Thymus Medulla | Q88595728 | ||
| Immune-bone interplay in the structural damage in rheumatoid arthritis | Q90325141 | ||
| Loss of Lgr4 inhibits differentiation, migration and apoptosis, and promotes proliferation in bone mesenchymal stem cells | Q90398444 | ||
| Icariin inhibits RANKL-induced osteoclastogenesis via modulation of the NF-κB and MAPK signaling pathways | Q90410507 | ||
| Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review | Q90672413 | ||
| The induction of RANKL molecule clustering could stimulate early osteoblast differentiation | Q90804420 | ||
| Improved RANKL production by memory B cells: A way for B cells promote alveolar bone destruction during periodontitis | Q91359664 | ||
| Pathogenic stromal cells as therapeutic targets in joint inflammation | Q93017920 | ||
| Sodium hydrosulfide inhibits the differentiation of osteoclast progenitor cells via NRF2-dependent mechanism. | Q46869857 | ||
| Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses | Q46891798 | ||
| Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. | Q47944184 | ||
| RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice | Q48039377 | ||
| RANKL and RANK: From Mammalian Physiology to Cancer Treatment. | Q48568949 | ||
| Inhibition of the TNF Family Cytokine RANKL Prevents Autoimmune Inflammation in the Central Nervous System | Q49133217 | ||
| Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings | Q49884599 | ||
| Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. | Q50048434 | ||
| RANKL: A therapeutic target for bone destruction in rheumatoid arthritis | Q50207113 | ||
| Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. | Q50335960 | ||
| Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway. | Q50455353 | ||
| Delta-like 4-mediated Notch signaling is required for early T-cell development in a three-dimensional thymic structure. | Q50586878 | ||
| Lymphotoxin β receptor regulates the development of CCL21-expressing subset of postnatal medullary thymic epithelial cells. | Q51068690 | ||
| Denosumab: Current Use in the Treatment of Primary Bone Tumors. | Q51822333 | ||
| The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. | Q51949099 | ||
| NF-kappa B-inducing kinase establishes self-tolerance in a thymic stroma-dependent manner. | Q52093900 | ||
| Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. | Q52558597 | ||
| Setting Up the Perimeter of Tolerance: Insights into mTEC Physiology. | Q52752332 | ||
| TNF superfamily members play distinct roles in shaping the thymic stromal microenvironment. | Q53138302 | ||
| The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. | Q53453365 | ||
| Selective estrogen receptor modulators in T cell development and T cell dependent inflammation. | Q53478926 | ||
| LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. | Q54200830 | ||
| Lymphotoxin signal promotes thymic organogenesis by eliciting RANK expression in the embryonic thymic stroma. | Q54380933 | ||
| Fyn positively regulates the activation of DAP12 and FcRγ-mediated costimulatory signals by RANKL during osteoclastogenesis. | Q54525746 | ||
| Altered Maturation of Medullary TEC in EphB-Deficient Thymi Is Recovered by RANK Signaling Stimulation. | Q54977053 | ||
| Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: a new therapy for human RANKL-dependent ARO. | Q55056509 | ||
| RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer | Q56892940 | ||
| Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation | Q57675158 | ||
| New and emerging concepts in the use of denosumab for the treatment of osteoporosis | Q58583955 | ||
| Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis | Q58588319 | ||
| Tumor-Stroma Interactions in Bone Metastasis: Molecular Mechanisms and Therapeutic Implications | Q38734435 | ||
| Natural products for treatment of bone erosive diseases: The effects and mechanisms on inhibiting osteoclastogenesis and bone resorption | Q38821799 | ||
| Murine Rankl-/- Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector | Q39014215 | ||
| Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis | Q39124107 | ||
| Developmentally regulated availability of RANKL and CD40 ligand reveals distinct mechanisms of fetal and adult cross-talk in the thymus medulla | Q39207497 | ||
| Inflammatory osteolysis: a conspiracy against bone | Q39343563 | ||
| Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis | Q39714931 | ||
| Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. | Q40164456 | ||
| Physiologic Thymic Involution Underlies Age-Dependent Accumulation of Senescence-Associated CD4+ T Cells | Q40200529 | ||
| LOX Fails to Substitute for RANKL in Osteoclastogenesis | Q40547452 | ||
| Osteoprotegerin-Mediated Homeostasis of Rank+ Thymic Epithelial Cells Does Not Limit Foxp3+ Regulatory T Cell Development. | Q40646125 | ||
| RBP-J imposes a requirement for ITAM-mediated costimulation of osteoclastogenesis | Q41831155 | ||
| RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla | Q41868543 | ||
| Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. | Q42133193 | ||
| Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. | Q42526719 | ||
| Osteoclast regulation of osteoblasts via RANK‑RANKL reverse signal transduction in vitro | Q42679472 | ||
| Graded attenuation of TCR signaling elicits distinct autoimmune diseases by altering thymic T cell selection and regulatory T cell function. | Q42965335 | ||
| Sequential phases in the development of Aire-expressing medullary thymic epithelial cells involve distinct cellular input | Q43809296 | ||
| Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis | Q44688981 | ||
| DJ-1 controls bone homeostasis through the regulation of osteoclast differentiation | Q46260785 | ||
| A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation | Q46427712 | ||
| RANK-Independent Osteoclast Formation and Bone Erosion in Inflammatory Arthritis | Q46515547 | ||
| Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells | Q46790944 | ||
| Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis. | Q34545263 | ||
| T cell-B cell thymic cross-talk: maintenance and function of thymic B cells requires cognate CD40-CD40 ligand interaction | Q34551079 | ||
| Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells | Q34576335 | ||
| Aire-dependent production of XCL1 mediates medullary accumulation of thymic dendritic cells and contributes to regulatory T cell development | Q34577749 | ||
| Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 | ||
| An evolutionary perspective on the mechanisms of immunosenescence | Q34987918 | ||
| Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. | Q35848843 | ||
| Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin | Q35913720 | ||
| Rank signaling links the development of invariant γδ T cell progenitors and Aire(+) medullary epithelium | Q36011240 | ||
| Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. | Q36229199 | ||
| FOXO1 inhibits osteoclastogenesis partially by antagnozing MYC. | Q36280893 | ||
| Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis | Q36402845 | ||
| Increased generation of Foxp3(+) regulatory T cells by manipulating antigen presentation in the thymus | Q36637209 | ||
| IRF7-dependent IFN-β production in response to RANKL promotes medullary thymic epithelial cell development | Q36718149 | ||
| Zoned out: functional mapping of stromal signaling microenvironments in the thymus | Q36732547 | ||
| Delta-like 4 is the essential, nonredundant ligand for Notch1 during thymic T cell lineage commitment. | Q36946535 | ||
| Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis | Q37039571 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene | Q37265676 | ||
| NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). | Q37302319 | ||
| Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis | Q37315396 | ||
| Cartilage damage and bone erosion are more prominent determinants of functional impairment in longstanding experimental arthritis than synovial inflammation. | Q37425952 | ||
| NF-κB signaling and bone resorption | Q37449635 | ||
| Bone loss in surgically ovariectomized premenopausal women is associated with T lymphocyte activation and thymic hypertrophy. | Q37570025 | ||
| Thymus microenvironment in human primary immunodeficiency diseases. | Q37617916 | ||
| Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT. | Q37631691 | ||
| Cytokine crosstalk for thymic medulla formation | Q37824947 | ||
| Mechanisms of T cell development and transformation. | Q37899181 | ||
| Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. | Q37973391 | ||
| Thymic epithelial cells: working class heroes for T cell development and repertoire selection | Q38010575 | ||
| New developments in osteoimmunology | Q38052462 | ||
| Osteoprotegerin: multiple partners for multiple functions | Q38119335 | ||
| Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts | Q38593977 | ||
| Inflammatory Cell Migration in Rheumatoid Arthritis: A Comprehensive Review | Q38618883 | ||
| Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. | Q38633393 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | central tolerance | Q606766 |
| signal transduction | Q828130 | ||
| bone disease | Q4941552 | ||
| P304 | page(s) | 629 | |
| P577 | publication date | 2019-03-29 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | The RANKL-RANK Axis: A Bone to Thymus Round Trip | |
| P478 | volume | 10 |
| Q89580277 | High frequency vaccination-induced immune stress reduces bone strength with the involvement of activated osteoclastogenesis in layer pullets |
| Q64967677 | Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions. |
| Q90631432 | Origins of Alterations to Rankl Null Mutant Mouse Dental Root Development |
| Q92701745 | Regulation of Hedgehog signaling Offers A Novel Perspective for Bone Homeostasis Disorder Treatment |
| Q89895783 | The Administration of 4-Hexylresorcinol Accelerates Orthodontic Tooth Movement and Increases the Expression Level of Bone Turnover Markers in Ovariectomized Rats |
| Q99237795 | When the Damage Is Done: Injury and Repair in Thymus Function |
Search more.